Denali Therapeutics Inc. (DNLI) has a negative trailing P/E of -6.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 14.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -15.03%, forward earnings yield 6.93%.
Criteria proven by this page:
Overall SharesGrow Score: 61/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.6 | -0.01 | 0.54 | 0.00 | - |
| 2017 | -2.7 | 0.05 | 0.50 | 0.00 | - |
| 2018 | -52.8 | 0.57 | 3.50 | 14.82 | - |
| 2019 | -8.4 | -0.02 | 4.22 | 62.43 | - |
| 2020 | 128.3 | -0.98 | 7.93 | 27.19 | - |
| 2021 | -18.7 | 0.04 | 5.63 | 111.38 | - |
| 2022 | -10.7 | -1.22 | 3.35 | 32.19 | - |
| 2023 | -20.3 | 0.34 | 2.86 | 8.92 | - |
| 2024 | -7.9 | -0.06 | 2.73 | 0.00 | - |
| 2025 | -5.7 | -0.36 | 2.86 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-13.49 | $0.00 | $-86.65M | - |
| 2017 | $-5.89 | $0.00 | $-88.19M | - |
| 2018 | $-0.39 | $129.16M | $-36.24M | -28.1% |
| 2019 | $-2.07 | $26.68M | $-197.61M | -740.7% |
| 2020 | $0.63 | $335.66M | $71.14M | 21.2% |
| 2021 | $-2.39 | $48.66M | $-290.58M | -597.2% |
| 2022 | $-2.60 | $108.46M | $-325.99M | -300.6% |
| 2023 | $-1.06 | $330.53M | $-145.22M | -43.9% |
| 2024 | $-2.57 | $0.00 | $-422.77M | - |
| 2025 | $-2.97 | $0.00 | $-512.54M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.58 | $-2.93 – $-2.05 | $58.31M | $5.45M – $172.7M | 15 |
| 2027 | $-2.49 | $-3.10 – $-1.38 | $136.77M | $19.07M – $282.01M | 14 |
| 2028 | $-0.75 | $-2.23 – $1.34 | $494.44M | $485.11M – $503.76M | 14 |
| 2029 | $0.14 | $-0.02 – $0.39 | $689.88M | $101.99M – $1.65B | 8 |
| 2030 | $1.68 | $-0.18 – $4.71 | $1.06B | $156.07M – $2.52B | 12 |
